CD19CD20-CAR.p40-T
/ Shenzhen University General Hospital
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
August 01, 2025
CAR-T: Efficacy and Safety of CD19CD20-CAR.p40-T in B-cell Lymphoma
(clinicaltrials.gov)
- P1/2 | N=20 | Recruiting | Sponsor: Shenzhen University General Hospital
New P1/2 trial • B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology
1 to 1
Of
1
Go to page
1